01 September 2022 : Clinical Research
High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy
Iwona Homa-Mlak1ACDEF*, Radosław Mlak1ACDEF, Anna Brzozowska2BDF, Marcin Mazurek1CEF, Tomasz Powrózek1CDE, Monika Prendecka-Wróbel1CEF, Aneta Szudy-Szczyrek2ADE, Piotr Dreher3CEF, Katarzyna Kamińska4F, Teresa Małecka-Massalska1ACEF, Alicja Wójcik-Załuska5CEGDOI: 10.12659/MSM.936857
Med Sci Monit 2022; 28:e936857
Table 6 Influence of demographic and clinical factors on nutritional risk assessed by NRS scale in HNC patients.
| Factor | NRS | |||
|---|---|---|---|---|
| <3 | ≥3 | pOR (95% CI) | ||
| Gender | Male | 30 (69.7%) | 13 (30.3%) | 0.51010.58 (0.11–2.96) |
| Female | 4 (57.1%) | 3 (42.8%) | ||
| Age (years) | ≥65 | 13 (61.9%) | 8 (38.1%) | 0.43331.62 (0.49–5.36) |
| <65 | 21 (72.4%) | 8 (27.6%) | ||
| Histopathological diagnosis | Carcinama planoepitheliale | 32 (69.6%) | 14 (30.4%) | 0.43110.44 (0.06–3.43) |
| Other | 2 (50%) | 2 (50%) | ||
| Tumor location | Upper and middle | 6 (54.5%) | 5 (45.5%) | 0.28432.12 (0.54–8.40) |
| Lower | 28 (71.8%) | 11 (28.2%) | ||
| Lower and middle | 2 (40%) | 3 (60%) | 0.17823.69 (0.55–24.73) | |
| Upper | 32 (71.1%) | 13 (28.9%) | ||
| T stage | T1–T2 | 7 (70%) | 3 (30%) | 0.87960.89 (0.20–4.01 |
| T3–T4 | 27 (67.5%) | 13 (32.5%) | ||
| N stage | N0 | 8 (50%) | 8 (50%) | 0.06683.25 (0.92–1.46) |
| N1–N3 | 26 (76.5%) | 8 (23.5%) | ||
| M stage | M0 | 32 (68.1%) | 15 (31.9%) | 0,95930,94 (0.07–11.16) |
| Mx and M1 | 2 (66.7%) | 1 (33.3%) | ||
| Performance status (ECOG) | 1 (n=29) | 31 (67.4%) | 15 (32.6%) | 0.75551.45 (0.14–15.16) |
| 2 (n=1) | 3 (75%) | 1 (25%) | ||
| Irisin | Low (| 21 (84%) | 4 (16%) | 0.01970.21 (0.05–0.78)* | |
| High (>Me) | 13 (52%) | 12 (48%) | ||
| * Statistically significant results. ECOG – Eastern Cooperative Oncology Group; M – metastatic spread; N – lymph node involvement; T – tumor site and size. | ||||